Daewon Pharmaceutical Co. Ltd. (003220.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7003220001

Price
8,530.00 KRW
Market cap
182.83 bn KRW
P/E (2025)
–
P/S (2025)
0.30
Dividend yield
2.93 %
Net margin
-0.23 %
Return on equity (ROE)
-0.52 %
Return on assets (ROA)
-0.22 %

Daewon Pharmaceutical Co. Ltd. financials

Fiscal year20242025
Revenue598.16 bn KRW605.43 bn KRW
Gross profit287.33 bn KRW272.79 bn KRW
Operating income28.22 bn KRW3.51 bn KRW
EBIT25.46 bn KRW9.77 bn KRW
Net income14.21 bn KRW-1.38 bn KRW
Diluted EPS – continuing operations662.96 KRW-64.37 KRW

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Daewon Pharmaceutical Co. Ltd.

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.